Objective: Lipin-1, encoded by LPIN1, is expressed in the major metabolically active tissues. Decreased expression of lipin-1 in adipose tissue correlates with increased insulin resistance, and tagging of the LPIN1 locus has shown that rs33997857, rs6744682, and rs6708316 associate with metabolic phenotypes, specifically body mass index (BMI) and fasting serum lipid levels, both on the individual single-nucleotide polymorphism level and with a three-marker haplotype. Our aim was to validate the reported findings in the Danish population. Design: In the present study, variants were analyzed in LPIN1 using case-control studies, haplotype analyses, and quantitative trait analyses in a population of 17 538 Danes. Methods: The three LPIN1 variants were genotyped in 17 538 Danes from four study populations of middle-aged people. This provided us with a statistical power O99% to replicate previous findings. Variants were analyzed individually and in haplotype combinations in studies of quantitative metabolic traits and in case-control studies. Results: None of the three variants were associated with the examined quantitative traits including BMI, waist circumference, blood pressure, fasting serum lipid concentrations, or plasma glucose or serum insulin concentrations in the fasting state and following an oral glucose tolerance test. Haplotypes were tested for association with quantitative traits; however, only nominal association with blood pressure (PZ0.04) and waist circumference (PZ0.04) was observed. In case-control studies, no association was found for individual variants or the three-marker haplotype. Conclusion: LPIN1 rs33997857, rs6744682, and rs6708316 did not associate with type 2 diabetes, obesity, or related quantitative metabolic phenotypes in the Danish population examined.
Introduction
Lipin-1 is abundantly expressed in adipose tissue and skeletal muscle, and the lipin-1 protein localizes to either the cytosol or the nucleus, which may be related to its two known functions (1): i) in the cytosol, lipin-1 acts as a phosphatidate phosphatase (PAP) enzyme converting phosphatidate to diacylglycerol during triglyceride biosynthesis (2, 3) and ii) lipin-1 localizes to the nucleus in adipocytes and hepatocytes, where it as a transcriptional coactivator interacts with the nuclear receptor peroxisome proliferator-activated receptor a (PPARa or PPARA as listed in the HUGO Database) and PPARg (PPARG) coactivator 1a (PPARGC1A) in a complex that modulates fatty acid oxidation gene expression (4) (5) (6) . Physiological roles of lipin-1 have been elucidated in mouse models where lipin-1 deficiency induces lipodystrophy caused by both deficiency in PAP and transcriptional coactivator activities (1, 7) . In contrast, lipin-1 overexpression in either adipose tissue or skeletal muscle induces obese phenotypes. Interestingly, the musclespecific lipin-1 transgenic mice show diminished energy expenditure and develop insulin resistance -probably secondary to increased PAP activity leading to triglyceride accumulation and altered muscle metabolism (8) .
Physiological studies in humans have demonstrated a similar direct correlation between lipin-1 expression levels in adipose tissue and insulin sensitivity (7, 9) . It has therefore been suggested that lipin-1 may promote efficient incorporation of fatty acids into adipocyte triglycerides, thereby preventing lipid deposition in other tissues where they could impair insulin action such as muscle and liver (2) . Finally, in human adipocytes, lipin-1 expression levels are directly correlated with glucose transporter 4 expression, which may increase glucose uptake, and with expression of PPARa and fatty acid oxidation genes, which may prevent fatty acid accumulation (1, 7) .
Based upon the comprehensive biological knowledge of lipin-1 in energy metabolism, human lipin-1 has been considered as an obvious biological candidate explaining some of the inter-individual variation in common metabolic phenotypes, and variants in LPIN1 have shown association with fasting serum insulin, body mass index (BMI), waist circumference, and obesity (10) (11) (12) . Furthermore, previous studies have found variants in LPIN1 to be associated with increased risk of hypertension (13) and nominally associated with increased BMI in a meta-analysis of 8504 individuals from four studies (14) . A study of 1520 Chinese individuals found a rare haplotype to be significantly associated with type 2 diabetes (PZ4!10 K4 ), but none of the investigated single nucleotide polymorphisms (SNPs) or haplotypes of LPIN1 were associated with quantitative metabolic traits (15) . However, in a recent population-based German study (nZ1674), tagging of the LPIN1 locus, a three-marker haploblock (rs33997857 A-allele, rs6744682 A-allele, and rs6708316 C-allele), was highly associated with several phenotypes related to the metabolic syndrome, especially decreased BMI (PZ4!10 K7 ) and decreased waist circumference (PZ3!10 K8 ) (16) . Attempts to replicate these findings in another German study sample were unsuccessful; however, an association with decreased fasting serum high-density lipoprotein (HDL)-cholesterol and increased risk of type 2 diabetes was observed (16) .
In the present study, we aim to replicate reported associations of LPIN1 rs33997857, rs6744682, and rs6708316 with common metabolic phenotypes in a Danish population.
Subjects and methods

Study participants
The LPIN1 variants were genotyped in 17 538 individuals ascertained from four different study groups: i) the Inter99 cohort, which is a population-based, randomized, nonpharmacological intervention study of middleaged individuals for the prevention of ischemic heart disease (nZ6266) conducted at the Research Centre for Prevention and Health in Glostrup, Copenhagen (ClinicalTrials.gov ID-no: NCT00289237) (17) , ii) the ADDITION Denmark screening study cohort (Anglo-Danish-Dutch Study of Intensive Treatment in People with Screen-Detected Diabetes in Primary Care) (ClinicalTrials.gov ID-no: NCT00237548) (18) , which involves individuals at high risk of type 2 diabetes screened in general practice (nZ8594), iii) a population-based group of unrelated middle-aged individuals (nZ667) examined at Steno Diabetes Center (Copenhagen, Denmark), and iv) unrelated diabetic patients (nZ2011) sampled through the out-patient clinic at Steno Diabetes Center. Study groups 1 and 3 underwent a standard 75-g oral glucose tolerance test (OGTT). An overview of the clinical characteristics of the four study groups is given in Supplementary Table 1, see section on supplementary data given at the end of this article. All study participants were Danes by self report, and informed written consent was obtained from all subjects before participation. The studies were approved by the regional ethical committees (Ethics Committee, Copenhagen County for study group 1, 3, and 4 and Ethics Committee, Aarhus County for study group 2), and were in accordance with the principles of the Helsinki Declaration.
Biochemical and anthropometrical measurements
Height and body weight were measured in light indoor clothes and without shoes, and BMI was calculated as weight (kg)/(height (m)) 2 . Waist circumference was measured in the standing position midway between the iliac crest and the lower costal margin, and hip circumference was measured at its maximum.
Blood samples were drawn after a 12-h overnight fast. Plasma glucose was analyzed by a glucose oxidase method (Granutest, Merck). HbA1c was measured by ion-exchange HPLC (normal reference range: 4.1-6.4%), and serum insulin, excluding des (31, 32) and intact proinsulin, was measured using an insulin kit (Auto-DELFIA, Perkin-Elmer/Wallac, Turku, Finland). Serum C-peptide concentrations were measured by a timeresolved fluoroimmunoassay (AutoDELFIA C-peptide kit; Perkin-Elmer/Wallac). Serum triglyceride, total cholesterol, and HDL-cholesterol were analyzed using enzymatic colorimetric methods (GPO-PAP and CHOD-PAP, Roche Molecular Biochemicals). Homeostasis model assessment of insulin resistance was calculated as described previously (19) . The OGTT-derived indices of insulin sensitivity (BIGTT-S I ) and b-cell function (BIGTT-acute insulin response) were calculated as described earlier (20) .
In the case-control studies, we used the WHO criteria for definitions of type 2 diabetes, obesity, hypertension, and dyslipidemia (21) . Type 2 diabetic patients were compared with glucose-tolerant subjects, overweight subjects (BMIR25 kg/m 2 ) were compared with lean subjects (BMI!25 kg/m 2 ), hypertensive patients (systolic blood pressure R140 mmHg and/or diastolic blood pressure R90 mmHg diastolic or treatment with antihypertensive drugs) were compared with normotensive subjects, and dyslipidemic patients (triglyceride R1.7 mmol/l or HDL %0.9 mmol/l for men and 1.0 mmol/l for women) were compared with normolipidemic subjects.
Genotyping
LPIN1 rs33997857, rs6744682, and rs6708316 were genotyped using KASPar (KBioscience, Hoddesdon, UK). Discordance between 1156 random duplicate samples was !0.09%, and the genotyping success rate was O97.3%. All genotype groups obeyed Hardy-Weinberg equilibrium (all PO0.2). The three variants form a haploblock spanning 9.9 kb between exon 10 and intron 13 based on a pairwise D 0 O0.8 (16) .
Statistical analysis
Fisher's exact test was applied to examine differences in allele frequencies and genotype distributions between affected and unaffected participants. A general linear model was used to test quantitative variables for differences between genotype groups among glucosetolerant and untreated participants. All analyses were performed using SPSS version 14.0 (Chicago, IL, USA) and RGui version 2.7.0 (http://www.r-project.org/). A P value of !0.05 was considered to be significant. Haplotype frequencies were estimated using the expectation-maximization algorithm, and association was evaluated by global and haplotype-specific score statistics. The global P value is an estimate of the overall effect of haplotypes in the statistical model, and the specific P value is an estimate of the effect of a specific haplotype compared with the effect of the remaining haplotypes. PHASE version 2.1.1 was used to estimate the haplotype combinations (22) . General linear models with adjustment for sex, age, and BMI were used to test a reference haplotype combination against the remaining haplotype combinations for differences in the frequency of factors of the metabolic syndrome, and a specific P value for each comparison was calculated. F-test (for continuous traits) and c 2 test (for binary traits) were used to calculate the global P value representing the fit to the model added by haplotype combinations compared with a model including only sex, age, and BMI.
The statistical power in case-control settings was determined using the CaTS power calculator version 0.0.2. Given the minor allele frequencies (MAFs; rs33997857, 1.9%; rs6744682, 34.1%; rs6708316, 35.8%) of the investigated LPIN1 variants, our study has a statistical power of more than 99% to detect an odds ratio of 1.15 in a case-control design for the two common variants (rs6744682 and rs6708316), whereas we need an odds ratio of 1.35 to reach a statistical power of 99% for the low-frequency variant (rs33997857). In the quantitative trait analyses, our study has a statistical power of 98% to detect an increase of 1 kg (76% for 0.5 kg) per allele for the two frequent variants, while the power was 73% to detect the same increase for the low-frequency variant (16% for 0.5 kg). Results LPIN1 rs33997857, rs6744682, and rs6708316 were genotyped in 17 538 Danes, and their MAFs in our study were in accordance with those reported in the HapMap project and previous studies (rs33997857, GZ1.9%; rs6744682, AZ34.1%; rs6708316, GZ35.8%). The three variants form a haploblock spanning 9.9 kb between exon 10 and intron 13. The two common variants, rs6708316 and rs6744682, were in high linkage disequilibrium (LD) (r 2 Z0.91 and D 0 Z0.99). Both were in low LD with the rare variant, rs33997857 (r 2 Z0.01 and D 0 Z0.99). The LD was very similar among the four study populations. We investigated the relationships of rs33997857, rs6744682, and rs6708316 with quantitative metabolic traits in the population-based Inter99 cohort of 6266 Danes. We were not able to show any significant association with any of the metabolic traits for the three investigated variants. The variants were analyzed using additive, recessive, and dominant models, but only minor differences were observed between the models. In Table 1 , data are given for rs6744682; the results for the two other LPIN1 variants are given in Supplementary Tables 2 and 3 , see section on supplementary data given at the end of this article.
For each of the three variants, four separate casecontrol studies were performed in which the LPIN1 genotype distribution and MAFs of type 2 diabetic patients were compared with those of glucose-tolerant subjects and those of type 2 diabetes patients were compared with those of glucose-tolerant normotensive subjects. Also, overweight subjects were compared with lean subjects, hypertensive patients were compared with normotensive subjects, and dyslipidemic patients were compared with normolipidemic subjects ( Table 2) . None of these case-control studies showed any significant association.
Five allelic haplotypes of LPIN1 were found in the haploblock. Each of them were analyzed in the population-based Inter99 cohort of 6266 Danes for potential associations with multiple quantitative traits Data are number of subjects with each genotype (% of each group) and frequencies of the minor allele (MAF) in percentages. All P values were calculated using Fisher's exact test, and were used to compare genotype distributions (P GD ) and MAFs (P MAF ). Values of serum insulin, values derived from insulin variables, and values of serum triglyceride were logarithmically transformed before statistical analysis. Calculated P values were adjusted for age, sex and BMI, and were calculated assuming an additive model.
related to metabolism. The data for the haplotype association are shown in Table 3 . We found only nominal association with blood pressure for haplotype 121 (PZ0.04). Furthermore, haplotype 112 was nominally associated with higher waist circumference (PZ0.04).
Discussion
Even though there is high similarity in the MAFs of the three investigated LPIN1 variants in our study participants compared with a previous German study of the same variants and even though our statistical power to demonstrate an effect of the common LPIN1 variants was high, we failed to replicate any of the reported associations between metabolic quantitative traits and the LPIN1 SNPs or haplotypes. The nominal association with diastolic blood pressure for haplotype 121 was in the opposite direction of what was previously reported (16) . The Danish individuals carrying the 121 LPIN1 haplotype showed a decreased diastolic blood pressure, whereas carriers in the previous study (16) had a slightly increased diastolic blood pressure. This discrepancy could be due to the fact that the haplotype frequencies are very different in the two study samples. Both haplotypes 121 and 112 are relatively rare, so we have only limited power to show whether these associations are true. In addition, none of our case-control studies for obesity, type 2 diabetes, dyslipidemia, or hypertension showed any significant associations to the selected LPIN1 variants. As discussed, several studies (10, 13, 14, 16) have investigated the role of LPIN1 variation in relation to metabolic traits; the results have, however, been highly inconsistent. The rs6744682 variant is, according to HapMap phase 3 build 36, in perfect LD with another variant, rs13392363, which has previously been analyzed in relation to blood pressure (10) . We analyzed several traits related to the phenotypes of the metabolic syndrome including systolic blood pressure, which has shown significant association among men in the German population (rs6744682 A-allele, nZ827) (16); still, no significant association was found in our study.
The other common LPIN1 variant that we investigated, rs6708316, is in almost perfect LD (r 2 Z0.96 according to HapMap) with rs2577262 -the A-allele of which was reported to associate with higher BMI in lean and obese men in a population of 511 Finnish individuals (10). We were not able to verify these findings in our much larger Danish population. We cannot exclude that variants in LPIN1 may have a significant impact on metabolic phenotypes. Since we investigate only three variants in a haplotype block, we might miss significant associations within the gene.
Functional studies have shown that lipin-1 is important in several metabolic pathways; however, common LPIN1 variants analyzed in the present study and previous LPIN1 reports show high inconsistency in relation to metabolic phenotypes. Also, the LPIN1 haplotype replication study among Germans (16) showed genotype effects different from the initial observations. When it comes to a potential impact of the low-frequency, nonsynonymous LPIN1 variant (rs33997857, Val494Met) which has a MAF of w2%, our present study lacks statistical power to be conclusive.
In conclusion, LPIN1 rs33997857, rs6744682, and rs6708316 do not associate with type 2 diabetes, obesity, or related quantitative metabolic phenotypes in the examined Danish population.
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